Related Experiment Video
Updated: May 8, 2026
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Multi-kinase modulation for colon cancer therapy
1Department of Neurosurgery; Massey Cancer Center; Virginia Commonwealth University; Richmond, VA USA.
Abstract:
It is now well recognized that in the vast majority of tumor types, for the approach of "kinase inhibition" to exhibit a significant effect, whether the data are from an in vitro assay, an animal model or the clinic, requires that multiple complementary kinases be simultaneously inhibited. This combined inhibition is not only kill the tumor cell but also to suppress and kill tumor cells that seek to avoid the initial induction of death processes via compensatory survival signaling mechanisms. Even within the broad brush definition of carcinomas from a particular organ, there are a range of mutations which present that will profoundly or sometimes more subtly change the paradigm for therapeutic intervention using multiple kinase inhibitor combinations. For example, in colorectal cancer the K-RAS oncogene frequently has an activating mutation implying that inhibition of RAF-MEK1/2-ERK1/2 signaling, but not an initiating receptor upstream of K-RAS, could have a therapeutic effect; however, some colon cell lines with the K-RAS mutation are still noted to be sensitive to upstream ERBB1 inhibitors. Also, compensatory feedback survival signaling loops can cause, after inhibition of a mutant active intracellular oncogenic kinase such as B-RAF V600E, a survival activation of growth factor receptors in a tumor cell. The clinical studies in the manuscript by Al-Marrawi et al. describe the rational combination of signaling inhibitors in a colon cancer patient whose tumor cells express a mutant active B-RAF V600E protein that signals into the MEK1/2-ERK1/2 pathway downstream of K-RAS; this is a particularly aggressive form of colon cancer for which few rational therapeutic interventions have been available until recent times.
Insights
Targeting multiple kinases simultaneously is crucial for effective cancer treatment, especially in aggressive colorectal cancer. This approach overcomes tumor resistance by inhibiting compensatory survival pathways, offering new therapeutic strategies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Kinase inhibition is a key cancer therapy, but often requires targeting multiple complementary kinases simultaneously.
- Tumor cells develop resistance through compensatory survival signaling mechanisms, necessitating combination therapies.
- Genetic mutations, such as in K-RAS and B-RAF, dictate specific therapeutic vulnerabilities and resistance patterns in cancers like colorectal cancer.
Purpose of the Study:
- To investigate the rational combination of signaling inhibitors for colon cancer patients with mutant B-RAF V600E.
- To address the therapeutic challenges posed by aggressive colorectal cancer driven by specific oncogenic mutations.
- To explore strategies for overcoming resistance mediated by compensatory survival signaling pathways.
Main Methods:
- Clinical studies examining the efficacy of combined signaling inhibitors.
- Analysis of tumor cell signaling pathways, including B-RAF V600E and downstream MEK1/2-ERK1/2.
- Evaluation of compensatory activation of growth factor receptors following kinase inhibition.
Main Results:
- Demonstrated a rational combination therapy approach for a specific colon cancer subtype.
- Highlighted the role of mutant B-RAF V600E in driving aggressive tumor signaling.
- Showcased the potential to overcome resistance mechanisms in colorectal cancer.
Conclusions:
- Combined kinase inhibition strategies are essential for effectively treating cancers with complex mutational landscapes.
- Targeting specific oncogenic drivers like B-RAF V600E in combination with other pathway inhibitors offers a promising therapeutic avenue for aggressive colorectal cancer.
- Understanding and targeting compensatory survival signaling is critical for improving treatment outcomes in oncology.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:15Drugs that Stabilize Microtubules